Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
37.65 CHF | -0.26% | +5.76% | +6.66% |
Sales 2024 * | 180M 200M | Sales 2025 * | 205M 227M | Capitalization | 452M 501M |
---|---|---|---|---|---|
Net income 2024 * | 20M 22.17M | Net income 2025 * | 36M 39.9M | EV / Sales 2024 * | 2.83 x |
Net Debt 2024 * | 57.88M 64.15M | Net Debt 2025 * | 12.51M 13.86M | EV / Sales 2025 * | 2.27 x |
P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
13.6
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.55% |
Latest transcript on Basilea Pharmaceutica AG
1 day | -0.26% | ||
1 week | +5.76% | ||
Current month | +7.11% | ||
1 month | +4.87% | ||
3 months | +4.29% | ||
6 months | -8.28% | ||
Current year | +6.66% |
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 14-08-31 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 08-12-31 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 17-04-26 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-12-31 |
Director/Board Member | 69 | 13-04-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 735 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 36 M€ | +4.92% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 37.65 | -0.26% | 22,578 |
24-03-27 | 37.75 | +0.67% | 28,753 |
24-03-26 | 37.5 | +1.63% | 22,909 |
24-03-25 | 36.9 | +0.14% | 20,891 |
24-03-22 | 36.85 | +3.51% | 41,895 |
Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.66% | 502M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |